FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.

doi:10.1016/j.cancergencyto.2008.02.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.

Cancer genetics and cytogenetics - 1 May 2008

Paiva Márcia, Marques Herlander, Martins Angelo, Ferreira Paula, Catarino Raquel, Medeiros Rui

Abstract excerpt

Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 surface marker expressed in neoplastic B-lymphoid cells. Combined with chemotherapy or alone, in maintenance/consolidation, it is used for the treatment of non-Hodgkin lymphoma (NHL). The role of a polymorphism in a specific Fc gamma receptor gene, FcgammaRIIa, in the clinical outcome of patients with NHL was investigated in this...

Topics

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD
Antineoplastic Agents
Drug Resistance, Neoplasm
Female
Gene Frequency
Humans
Lymphoma, Non-Hodgkin
Male
Middle Aged

Source

Open in PubMed

Identifiers

PMID: 18474295
DOI: 10.1016/j.cancergencyto.2008.02.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pharmacogenetics

Polymorphism, Single Nucleotide

Prognosis

Receptors, IgG